2Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome[J]. Ann Neurol , 1990, 27: S21-S24.
3Clarence C Tam , Sarah J O'Brien, Irene Petersen, et al. Guillain-Barre syndrome and preceding infection with campylobacter,influenza and Epstein-Barr virus in the general practice research database[J]. Plos One,2007,2 (4) :344.
4Asbury. CSF tau protein:a new prognostic marker for Guillain- Barre syndrome [J]. Neurology,2007,68 (17):1438 -1439.
5Piazza O, Esposito G,De Robertis E. S100B in Guillain-Barre syndrome[J]. British Journal of Anaesthesia, 2006,96 ( 1 ) : 141- 142.
6Linda J,Van Eldik,Wainwright MS. The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain [J]. Restorative Neurol Neurosci,2003,21 (3) : 97-108.
7Beauddeux J, Dequen L, Fog lietti M. Pathophysmlogic aspects of S100B protein: a new biologieal marker of brain pathology [J]. Ann Biol Clin(Paris) ,1999,57(3) :261.
8Marquardt G, Setzer M, Seifeft V. Protein S100b for individual prediction of functional outcome in spinal[J]. Epidural Empyemaine ,2004,29(1) :59-62.
9Rothermundt M,Petets M, Prehn JH. S100b in brain damage and neurodegeneration[J]. Microsci Ces Tech, 2003,60 (6): 614-632.
10Arch V, Peters M, Erfurth A. S100B and response to treatment in major depression:a pilot study[J]. Eur Neuropsychopharmacol,2003,13(4) :235-239.
